(July 2, 2024, 2:24 PM EDT) -- SAN FRANCISCO — Parties in an appeal pending in the Ninth Circuit U.S. Court of Appeals on whether a lower court erred in refusing to allow a group of anti-abortion states to intervene in a case filed by other states and the District of Columbia that sued the U.S. Food and Drug Administration to block any changes to the FDA’s approval of mifepristone XE "mifepristone" and subsequent changes to its prescribing practices filed supplemental briefs to opine on how a recent U.S. Supreme Court decision impacts their arguments....